VANCOUVER, July 17 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) announced today that it has entered into an agreement with Dompé pha.r.ma S.p.A. (Dompé) for clinical manufacture and commercial supply of PRX321, its lead product candidate in development for the treatment of primary brain cancer. Under the terms of the agreement, Dompé will manufacture PRX321 according to current Good Manufacturing Practice at its state-of-the-art facility in Italy for the upcoming pre-pivotal clinical trial and has committed to supply commercial batches for a period of 5 years following product registration. Terms of the final agreement have not been released.
